Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally. The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia; and estradiol transdermal sprays for women for the treatment of moderate to severe hot flushes associated with menopause under the Lenzetto and Evamist brand names. It also provides laboratory and product development services, including in vitro release testing; formulation development; stability and quality check; analytical; generic and pharma development; regulatory; project management and technology transfer; consulting; and co-development services. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Frequently asked questions
What sector does Acrux Limited (ARUXF) operate in?
Acrux Limited belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Acrux Limited (ARUXF) current stock price?
As of the latest data, Acrux Limited stock price is $0.00, with a previous close of $0.00.
What is Acrux Limited (ARUXF) current market capitalization?
Acrux Limited market cap is approximately 61.22 thousand.
What is Acrux Limited (ARUXF) EBITDA?
Acrux Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -631.11 thousand.
Does Acrux Limited (ARUXF) pay dividends?
No. Acrux Limited does not pay a dividend.
What is Acrux Limited (ARUXF) beta (volatility) score?
Acrux Limited has a beta of 1.020, meaning its volatility is roughly in line with the market.
